Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis

Published:2016-04-08 Issue:11 Volume:43 Page:1109-1123
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Noureddin M.¹,Anstee Q. M.²,Loomba R.³⁴⁵

Affiliation:

1. Fatty Liver Program; Division of Digestive and Liver Diseases; Comprehensive Transplant Center; Cedars-Sinai Medical Center; Los Angeles CA USA

2. Liver Research Group; Institute of Cellular Medicine; The Medical School; Newcastle University; Newcastle-upon-Tyne UK

3. Division of Gastroenterology; University of California, San Diego; La Jolla CA USA

4. Division of Epidemiology; University of California, San Diego; La Jolla CA USA

5. NAFLD Research Center; University of California, San Diego; La Jolla CA USA

Funder

American Gastroenterological Association

T. Franklin Williams Scholarship Award

Atlantic Philanthropies

John A. Hartford Foundation

Association of Specialty Professors

Higher Education Funding Council for England

Horizon 2020 Framework Program of the European Union

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13620/fullpdf

Reference136 articles.

1. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008;Younossi;Clin Gastroenterol Hepatol,2011

2. Human fatty liver disease: old questions and new insights;Cohen;Science,2011

3. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies;Singh;Clin Gastroenterol Hepatol,2015

4. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management;McPherson;J Hepatol,2015

5. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease;Angulo;Gastroenterology,2015

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease;Cureus;2023-10-13

2. Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes;World Journal of Hepatology;2023-04-27

3. Understanding the Potential Role of Nanotechnology in Liver Fibrosis: A Paradigm in Therapeutics;Molecules;2023-03-20

4. Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis;Alimentary Pharmacology & Therapeutics;2023-01-17

5. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology;Clinical Therapeutics;2023-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3